Latest Licensing News

PARKD has inked a pivotal five-year exclusive licensing agreement with Fielders, a BlueScope Steel division, to commercialise its innovative MDSB® and MDSS® products in Australia and explore international expansion.

New World Resources has secured a critical federal permitting milestone for its Antler Copper Project, setting a clear path to full approval within 12 months and construction commencement in H2 2025.

AdAlta Limited is accelerating its 'East to West' cellular immunotherapy strategy, aiming to bridge Asian innovation with Western clinical development and manufacturing to target solid cancers. The company plans to secure three assets by the end of 2025 and initiate clinical trials, positioning itself as a leader in this emerging market.

Neuren Pharmaceuticals has secured a pivotal FDA Type C Meeting to discuss primary efficacy endpoints for its Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, advancing its rare disease drug development.

Lindian Resources has awarded a $1.3 million contract to Mota-Engil for the construction of a critical access road at its Kangankunde Rare Earths Project in Malawi, marking a key milestone in project development and local infrastructure enhancement.

Blackstone Minerals is set to merge with IDM International, combining expertise and local presence to advance exploration of the world-class Mankayan copper-gold porphyry project in the Philippines.

Arizona Lithium has unveiled a detailed, phased development plan for its Prairie Lithium Project, aiming to become North America’s first commercial lithium brine producer. The company targets initial production in 2025 with a modest capital outlay and scalable expansion strategy.

Blackstone Minerals has entered a binding scheme to acquire IDM International, securing the world-class Mankayan Copper-Gold Project in the Philippines. This merger positions Blackstone as a significant player in critical energy transition metals with promising exploration upside.

AdAlta has fast-tracked its cellular immunotherapy growth by signing two new term sheets for clinical-stage CAR-T products from Asia, pivoting to focus on in-licensing and clinical trials while winding down internal R&D on its antifibrotic drug AD-214.

Krakatoa Resources has identified significant potential extensions of antimony and gold mineralisation at its Zopkhito Project in Georgia, supported by advanced induced polarisation modelling. The company is poised to advance exploration with drilling and resource estimation in 2025.

Neurizon Therapeutics has been granted a pivotal US patent for its lead drug candidate NUZ-001, extending protection until 2039 and enhancing its commercial and clinical positioning in neurodegenerative disease treatment.

Audeara Limited has landed a significant US$917,000 follow-up purchase order from a global music instrument manufacturer, reinforcing the commercial viability of its hearing technology and expanding its licensing footprint.